Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 2 of 15

 
 

Zoetis (NYSE:ZTS)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$220.38 (17.7% Upside)

About Zoetis

Zoetis logoZoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/18/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$200.00 ➝ $210.00
8/27/2024Stifel NicolausReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/14/2024Piper SandlerBoost Price TargetOverweight ➝ Overweight$195.00 ➝ $210.00
8/12/2024BTIG ResearchBoost Price TargetBuy ➝ Buy$220.00 ➝ $225.00
8/9/2024ArgusUpgradeStrong-Buy
8/5/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$180.00 ➝ $200.00
7/25/2024BTIG ResearchInitiated CoverageBuy$220.00
5/8/2024HSBCLower Price TargetBuy ➝ Buy$230.00 ➝ $225.00
5/6/2024The Goldman Sachs GroupLower Price TargetBuy ➝ Buy$223.00 ➝ $196.00
4/30/2024Stifel NicolausLower Price TargetBuy ➝ Buy$195.00 ➝ $180.00
 

CRUSHED: How Biden's Replacement Will Devastate Your 401(k)! (Ad)

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<